tag chemotherapy 
pharmaphorum
JANUARY 5, 2022
Teliso-V is currently in a 233-patient phase 2 study (LUMINOSITY) involving subjects with c-Met-positive, non-squamous NSCLC as a second- or third-line treatment after chemotherapy, immunotherapy with checkpoint inhibitors or drugs targeted at specific mutations. Preliminary results from that study showed a 53.8%
Drug Discovery World
OCTOBER 31, 2022
Click’ chemistry used to tag proteins made by cancer cells. Targeted colon cancer treatment overcomes chemotherapy resistance. A team from the University of Geneva (UNIGE) has found a way to overcome chemotherapy resistance in colorectal cancer. Merck and Moderna to develop personalised cancer vaccine.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JANUARY 11, 2022
The DTx, called BNT200, is described as a first-of-its-kind DTx to treat anxiety and depression in adults with acute myeloid leukaemia (AML) who are hospitalised for a regimen of high-intensity induction chemotherapy. The DTx is an on-demand stress management intervention with content synchronised with high-intensity chemotherapy treatment.
pharmaphorum
OCTOBER 29, 2021
Trodelvy has already established itself as a go-to therapy for TNBC patients whose disease has progressed after prior treatments, says Gilead, while Keytruda is approved as a first-line therapy for the cancer in combination with chemotherapy, in patients with PD-L1 scores of 10 or more. While its headline revenue of $7.4
pharmaphorum
DECEMBER 23, 2021
Patritumab deruxtecan achieved an overall response rate of 25% when given as a therapy to patients with EGFR-mutated NSCLC whose cancer had progressed despite treatment with a third-generation EGFR inhibitor like AstraZeneca’s Tagrisso (osimertinib) and platinum-based chemotherapy.
pharmaphorum
APRIL 27, 2022
The coveted status has been awarded to the HER2-targeting antibody-drug conjugate (ADC) on the back of the DESTINY-Breast04 trial results, unveiled in February, which involved patients with HER2-low, unresectable and/or metastatic breast cancer previously treated with one to two prior lines of chemotherapy.
pharmaphorum
APRIL 5, 2022
The one-year survival rate with the drug was 73%, compared to 58% in a group receiving standard-of-care – off-label immune checkpoint inhibitors used for other forms of melanoma like Merck & Co’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Yervoy (ipilimumab) or chemotherapy with dacarbazine.
Expert insights. Personalized for you.
109 
Let's personalize your content